

Xbrane Biopharma AB (publ) ("Xbrane" or "the company") appoints Jane Benyamin as acting Chief Financial Officer.

Xbrane announces today that it has appointed Jane Benyamin as acting CFO as of January 9, 2025. As previously announced, the company's current CFO, Anette Lindqvist, is stepping down from the role of CFO with the intention of reducing her operational work to retire.

Jane has experience from several senior finance roles within Life Science from Bluefish Pharmaceuticals, Pensa Pharma and Medivir among others.

"I welcome Jane to Xbrane and I am convinced that her experience from the industry will be very valuable in the future," says Martin Åmark, CEO of Xbrane. "At the same time, I want to thank Anette Lindqvist for her valuable efforts as CFO and wish her all the best in the future"

Jane Benyamin will be acting CFO until further notice starting today, January 9, 2025. Anette Lindqvist will be available for a period to ensure a smooth transition.

Contacts

Martin Åmark, CEO

E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR

E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Attachments

[Xbrane Biopharma AB \(publ\) \("Xbrane" or "the company"\) appoints Jane Benyamin as acting Chief Financial Officer.](#)